NCT06898372View on ClinicalTrials.gov

Evaluate the Efficacy of Anti-Jak1 Inhibitors as Treatment for Patients With Aicardi-Goutières Syndrome

CompletedOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

April 7, 2024

Primary Completion Date

December 18, 2024

Study Completion Date

December 18, 2024

Conditions
Aicardi-Goutières Syndrome (AGS)
Interventions
DRUG

JAK Inhibitor

The retrospective analysis will examine the effects of Janus Kinase 1/2 (JAK1/2) inhibitors, such as Baricitinib and Ruxolitinib, on neurological symptoms and brain MRI.

Trial Locations (1)

56128

IRCCS Stella Maris Foundation, Pisa

All Listed Sponsors
lead

IRCCS Fondazione Stella Maris

OTHER

NCT06898372 - Evaluate the Efficacy of Anti-Jak1 Inhibitors as Treatment for Patients With Aicardi-Goutières Syndrome | Biotech Hunter | Biotech Hunter